Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes—A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies

This publication has 24 references indexed in Scilit:

• Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase
  Journal of Biological Chemistry, 2003
• Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777
  International Immunopharmacology, 2002
• Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow
  Immunological Reviews, 2000
• dNTP pools imbalance as a signal to initiate apoptosis
  Cellular and Molecular Life Sciences, 1996
• PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat bloodin vitro
  Inflammation Research, 1993
• Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages
  International Journal of Immunopharmacology, 1988
• Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency.
  Archives of Disease in Childhood, 1987
• Toxicity of naturally occuring purine deoxyribonucleosides
  Pharmacology & Therapeutics, 1980
• An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunity
  Clinica Chimica Acta, 1976
• NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY
  The Lancet, 1975